IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of comprehensive income

in CHF 1 000

 

Notes

 

01.01.–30.09.2023

 

01.01.–30.09.2022

 

01.07.–30.09.2023

 

01.07.–30.09.2022

Operating income

 

 

 

 

 

 

 

 

 

 

Net gains from securities

 

3

 

 

 

 

220 509

Interest income

 

 

 

17

 

 

 

Foreign exchange gains

 

 

 

600

 

1 258

 

100

 

478

Other income

 

 

 

5

 

4

 

 

1

 

 

 

 

622

 

1 262

 

100

 

220 988

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Net losses from securities

 

3

 

(285 455)

 

(290 136)

 

(39 135)

 

Finance expenses

 

 

 

(4 219)

 

(949)

 

(1 669)

 

(358)

Administrative expenses

 

6

 

(23 276)

 

(29 269)

 

(6 981)

 

(9 369)

Other expenses

 

 

 

(3 350)

 

(3 498)

 

(690)

 

(964)

 

 

 

 

(316 300)

 

(323 852)

 

(48 475)

 

(10 691)

Profit/(loss) before tax

 

7

 

(315 678)

 

(322 590)

 

(48 375)

 

210 297

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

 

(45)

 

(58)

 

(15)

 

(19)

Profit/(loss) for the period

 

 

 

(315 723)

 

(322 648)

 

(48 390)

 

210 278

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive profit/(loss) for the period

 

 

 

(315 723)

 

(322 648)

 

(48 390)

 

210 278

 

 

 

 

 

 

 

 

 

 

 

Income per share in CHF

 

8

 

(5.76)

 

(5.86)

 

(0.89)

 

3.83

Diluted income per share in CHF

 

8

 

(5.76)

 

(5.86)

 

(0.89)

 

3.83

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer